专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20170183390A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF 审中-公开
公开(公告)号：US20170183390A1
公开(公告)日：2017-06-29
申请号：US15424260
申请日：2017-02-03
申请人： THE CHILDREN'S MEDICAL CENTER CORPORATION
发明人： Timothy Alan SPRINGER , Xianchi DONG , Chafen LU
IPC分类号： C07K14/705 , G06F19/00 , G01N33/68
CPC分类号： C07K14/70546 , A61K38/1777 , C07K2299/00 , C07K2319/00 , G01N33/6872 , G06F19/701
摘要： Described herein are modified integrin α and/or β headpiece polypeptides, and crystallizable integrin polypeptide dimers comprising a modified integrin α and/or β headpiece polypeptide and a disulfide bond linking the two integrin headpiece polypeptide subunits. Methods for using the modified integrin α and/or β headpiece polypeptides and the integrin polypeptide dimers are also provided herein. For example, methods for characterizing integrin-ligand interaction and identifying integrin ligands are also provided herein. In some embodiments, the identified integrin ligands can be used as inhibitors of integrins.

72. 发明申请

US20170176420A1 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS 审中-公开
公开(公告)号：US20170176420A1
公开(公告)日：2017-06-22
申请号：US15440319
申请日：2017-02-23
申请人： The Children's Medical Center Corporation , The United States of America, As Represented by the Secretary, Department of Health & Human Servic
发明人： Anjana Rao , Mamta Tahiliani , Kian Peng Koh , Suneet Agarwal , Aravind Iyer
IPC分类号： G01N33/53 , C12N5/074 , G01N33/574
CPC分类号： C12Q1/6827 , C12N5/0018 , C12N5/0607 , C12N5/0637 , C12N5/0696 , C12N9/0071 , C12N15/873 , C12N2501/15 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2501/70 , C12N2501/71 , C12N2501/999 , C12N2506/1307 , C12N2506/1353 , C12N2510/00 , C12Q1/26 , C12Q1/6806 , C12Q1/6869 , C12Q1/6886 , C12Q2521/531 , C12Q2522/10 , C12Q2537/164 , C12Q2600/154 , G01N33/5011 , G01N33/5308 , G01N33/57426 , G01N33/57484 , G01N33/57496 , G01N2500/00
摘要： The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

73. 发明申请

US20170175085A1 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS 审中-公开
公开(公告)号：US20170175085A1
公开(公告)日：2017-06-22
申请号：US15440424
申请日：2017-02-23
申请人： The Children's Medical Center Corporation , The United States of America, As Represented by the Secretary, Department of Health & Human Servi
发明人： Anjana Rao , Mamta Tahiliani , Kian Peng Koh , Suneet Agarwal , Aravind Iyer
IPC分类号： C12N5/074 , G01N33/574 , G01N33/53
CPC分类号： C12Q1/6827 , C12N5/0018 , C12N5/0607 , C12N5/0637 , C12N5/0696 , C12N9/0071 , C12N15/873 , C12N2501/15 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2501/70 , C12N2501/71 , C12N2501/999 , C12N2506/1307 , C12N2506/1353 , C12N2510/00 , C12Q1/26 , C12Q1/6806 , C12Q1/6869 , C12Q1/6886 , C12Q2521/531 , C12Q2522/10 , C12Q2537/164 , C12Q2600/154 , G01N33/5011 , G01N33/5308 , G01N33/57426 , G01N33/57484 , G01N33/57496 , G01N2500/00
摘要： The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

74. 发明申请

US20170137800A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES 审中-公开
公开(公告)号：US20170137800A1
公开(公告)日：2017-05-18
申请号：US15322274
申请日：2015-07-08
申请人： The Children's Medical Center Corporation
发明人： Umut Ozcan , Hilde Herrema
IPC分类号： C12N9/90
摘要： Compositions containing an FKBP 11 peptide (i.e., FKBP11 polypeptide, a variant or a fragment thereof), a fusion protein containing an FKBP11 peptide, or a nucleic acid encoding an FKBP 11 peptide are disclosed. Also disclosed are methods of reducing blood glucose levels, improving glucose tolerance, decreasing hepatic gluconeogenic activity and/or improving insulin sensitivity in a subject, by administering a composition containing an FKBP 11 peptide or a fusion protein containing an FKBP11 peptide. The methods can include administering nucleic acids encoding an FKBP 11 peptide or a fusion protein containing an FK BP11 peptide, to the subject, or cells expressing the nucleic acids. Kits containing an FKBP 11 peptide, are also provided.

75. 发明授权

US09474717B2 Vaccine nanotechnology 有权
公开(公告)号：US09474717B2
公开(公告)日：2016-10-25
申请号：US13844100
申请日：2013-03-15
申请人： Massachusetts Institute of Technology , The Children's Medical Center Corporation , President and Fellows of Harvard College , The Brigham and Women's Hospital, Inc.
发明人： Ulrich H. von Andrian , Omid C. Farokhzad , Robert S. Langer , Tobias Junt , Elliott Ashley Moseman , Liangfang Zhang , Pamela Basto , Matteo Iannacone , Frank Alexis
IPC分类号： A61K39/12 , A61K39/00 , A61K9/14 , A61K47/48 , A61K39/39
CPC分类号： A61K9/14 , A61K39/00 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K47/6911 , A61K47/6937 , A61K2039/555 , A61K2039/60 , Y02A50/464 , Y02A50/472
摘要： The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.

76. 发明申请

US20150250753A1 COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF 有权
标题翻译：用于治疗肥胖症的化合物及其使用方法
公开(公告)号：US20150250753A1
公开(公告)日：2015-09-10
申请号：US14431412
申请日：2013-09-26
申请人： THE CHILDREN'S MEDICAL CENTER CORPORATION , THE MASSACHUSETTS GENERAL HOSPITAL
发明人： Umut Ozcan , Joseph Majzoub , Ralph Mazitschek , Isin Cakir , Serkan Cabi
IPC分类号： A61K31/198 , A61K31/19 , A61K38/22 , A61K31/195 , A61K31/194 , A61K45/06 , A61K31/192
CPC分类号： A61K31/198 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/195 , A61K38/2264 , A61K45/06 , A61K2300/00
摘要： Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.
摘要翻译：本文提供五环三萜减肥剂。还提供了含有治疗有效量的一种或多种减肥剂或其药学上可接受的盐或前药与一种或多种药学上可接受的赋形剂组合的药物制剂。药物制剂可以施用于肥胖前，肥胖或病态肥胖的患者，以诱导体重减轻，减少体脂肪，减少食物摄入，改善葡萄糖体内平衡，预防肥胖或其组合。减肥剂也可以与瘦素或瘦蛋白类似物共同施用。

77. 发明申请

US20140348896A1 Hydrophobic Tissue Adhesives 有权
标题翻译：疏水组织粘合剂
公开(公告)号：US20140348896A1
公开(公告)日：2014-11-27
申请号：US14286743
申请日：2014-05-23
申请人： Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc. , The Children's Medical Center Corporation
发明人： Jeffrey M. Karp , Pedro del Nido , Nora Lang , Robert S. Langer , Maria Jose M.N. Pereira , Yuhan Lee
IPC分类号： A61L24/04 , C08G63/91 , A61L24/00
CPC分类号： A61L24/046 , A61L15/26 , A61L15/42 , A61L15/58 , A61L24/001 , A61L2400/18 , C08F2222/1073 , C08G63/47 , C08G63/914 , C08L67/04
摘要： Pre-polymers for use as tissue sealants and adhesives, and methods of making and using thereof are provided. The pre-polymers have flow characteristics such that they can be applied through a syringe or catheter but are sufficiently viscous to remain in place at the site of application and not run off the tissue. The pre-polymers are also sufficiently hydrophobic to resist washout by bodily fluids. The pre-polymers are stable in bodily fluids; that is the pre-polymer does not spontaneously crosslink in bodily fluids absent the presence of an intentionally applied stimulus to initiate crosslinking. Upon crosslinking, the adhesive exhibits significant adhesive strength in the presence of blood and other bodily fluids. The adhesive is sufficiently elastic that it is able to resist movement of the underlying tissue. The adhesive can provide a hemostatic seal. The adhesive is biodegradable and biocompatible, causing minimal inflammatory response.
摘要翻译：提供用作组织密封剂和粘合剂的预聚物，以及其制备和使用方法。预聚物具有流动特性，使得它们可以通过注射器或导管施用，但足够粘稠以在施用部位保持就位，而不会从组织中流出。预聚物也足够疏水以抵抗体液冲洗。预聚物在体液中稳定; 也就是预聚物在体液中不会自发交联，而不存在有意施加的刺激以引发交联。交联时，粘合剂在血液和其他体液存在下显示出显着的粘合强度。粘合剂具有足够的弹性，使得其能够抵抗下面的组织的运动。粘合剂可以提供止血密封。粘合剂是可生物降解和生物相容的，导致最小的炎症反应。

78. 发明申请

US20140303234A1 METHODS FOR THE MODULATION OF ANGIOGENESIS 审中-公开
标题翻译：血管生成调节方法
公开(公告)号：US20140303234A1
公开(公告)日：2014-10-09
申请号：US14226179
申请日：2014-03-26
申请人： THE CHILDREN'S MEDICAL CENTER CORPORATION
发明人： Donald E. INGBER , Akiko MAMMOTO
IPC分类号： C12N15/113 , A61K45/06 , A61K31/7088
CPC分类号： C12N15/113 , A61K31/7088 , A61K45/06 , C12N2310/14
摘要： The present invention relates to methods and compositions for promoting or inhibiting capillary endothelial (CE) cell migration, promoting or inhibiting the formation of CE networks and promoting or inhibiting angiogenesis. Some embodiments relate to methods and compositions for treating angiogenesis-related disorders characterized by loss or decreased angiogenesis. One aspect relates to the use of at least one pro-angiogenic agent selected from at least one of an p190RhoGAP inhibitor, a TFII-I inhibitor a GATA-2 activator for promoting the formation of CE networks and angiogenesis, and methods for treating angiogenesis-related disorders characterized by loss or decreased angiogenesis. Another aspect of the invention related to use of at least one anti-angiogenic agent selected from at least one of an p190RhoGAP activator, a TFII-I activator a GATA-2 inhibitor for inhibiting the formation of CE networks and inhibiting angiogenesis, and methods for treating angiogenesis-related disorders characterized by uncontrolled or elevated angiogenesis.
摘要翻译：本发明涉及用于促进或抑制毛细血管内皮细胞迁移，促进或抑制CE网络形成和促进或抑制血管发生的方法和组合物。一些实施方案涉及用于治疗以血管生成减少或减少为特征的血管生成相关病症的方法和组合物。一个方面涉及使用至少一种选自p190RhoGAP抑制剂，TFII-1抑制剂，GATA-2激活剂中的至少一种促血管生成剂促进CE网络形成和血管生成的方法，以及用于治疗血管生成 - 特征在于损失或减少血管生成的相关疾病。本发明的另一方面涉及至少一种选自p190RhoGAP激活剂，TFII-1激活剂，GATA-2抑制剂中的至少一种的抗血管生成剂用于抑制CE网络形成和抑制血管发生的方法，以及用于治疗以不受控或升高的血管发生为特征的血管生成相关病症。

79. 发明授权

US12146162B2 Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells by episomal plasmid gene transfer 有权
公开(公告)号：US12146162B2
公开(公告)日：2024-11-19
申请号：US18147554
申请日：2022-12-28
申请人： THE CHILDREN'S MEDICAL CENTER CORPORATION
发明人： George Q. Daley
IPC分类号： C12N5/0789 , A61K35/28
CPC分类号： C12N5/0647 , A61K35/28 , C12N2500/24 , C12N2500/38 , C12N2500/44 , C12N2501/105 , C12N2501/115 , C12N2501/125 , C12N2501/14 , C12N2501/145 , C12N2501/15 , C12N2501/165 , C12N2501/2303 , C12N2501/2306 , C12N2501/2311 , C12N2501/26 , C12N2501/32 , C12N2501/41 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/605 , C12N2501/606 , C12N2501/608
摘要： Embodiments herein relate to in vitro production methods of hematopoietic stem cell (HSC) and hematopoietic stem and progenitor cell (HSPC) that have long-term multilineage hematopoiesis potentials upon in vivo engraftment. The HSC and HSPCs are derived from pluripotent stem cells-derived hemogenic endothelia cells (HE) by non-integrative episomal vectors-based gene transfer.

80. 发明授权

US12109242B2 Use of alveolar or airway organoids for the treatment of lung diseases and disorders 有权
公开(公告)号：US12109242B2
公开(公告)日：2024-10-08
申请号：US17074118
申请日：2020-10-19
申请人： THE CHILDREN'S MEDICAL CENTER CORPORATION
发明人： Carla F. Kim , Sharon M. Louie , Erhan Ararat , David Raiser
IPC分类号： C12N5/071 , A01K67/0271 , A61K9/00 , A61K35/42 , A61K45/06 , A61K49/00 , C12N5/00
CPC分类号： A61K35/42 , A01K67/0271 , A61K9/007 , A61K9/0073 , A61K45/06 , A61K49/0008 , C12N5/0062 , C12N5/0688 , C12N5/0697 , A01K2207/12 , A01K2227/105 , A01K2267/0337 , C12N2506/02 , C12N2506/27 , C12N2506/45 , C12N2513/00
摘要： Various aspects described herein provide methods of generating alveolar or alveolar/airway organoids from a population of lung cells to differentiate into alveolar or alveolar/airway organoids. Also provided herein are methods and compositions for treating lung disease comprising transplantation of the alveolar or alveolar/airway organoids, or a cell isolated therefrom to a subject.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式